ASCO 2023 | MATISSE: nivolumab in cutaneous squamous cell carcinoma

Charlotte Zuur, Leiden University Medical Centre, Leiden, The Netherlands, outlines the primary objectives and results of the Phase II MATISSE study (NCT02760498) of nivolumab and nivolumab plus ipilimumab (two monoclonal antibodies targeting PD1 and CTLA-4 respectively) in extensive cutaneous squamous cell carcinoma (SCC). The randomised trial enrolled 40 patients with an indication for curative surgery with or without radiotherapy; the study aimed to improve patients’ clinical prospects through immunotherapy and de-escalate surgery and radiotherapy. Dr Zuur shared the promising results of the immunotherapy, stating 90% of patients who refused surgery displayed disease-free survival of 1 year. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved